
    
      The total duration of the study will be 6 years (4 years of patient enrollment and 2
      additional years of clinical follow-up). Assessment for disease recurrence and survival will
      be conducted every 6 months (with a phone call/secure email, medical records or follow up
      visit) from the end of treatment for a total of 2 years, until the completion of the trial or
      until documented disease recurrence.
    
  